NIH Funding Opportunities (RSS Feed)

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

November 19, 2020

Funding Opportunity RFA-CA-21-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

November 19, 2020

Funding Opportunity RFA-CA-21-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

November 19, 2020

Funding Opportunity RFA-CA-21-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

November 19, 2020

Funding Opportunity RFA-CA-21-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Initiative for Maximizing Student Development (IMSD) (T32 - Clinical Trial Not Allowed)

November 19, 2020

Funding Opportunity PAR-21-025 from the NIH Guide for Grants and Contracts. The goal of the Initiative for Maximizing Student Development (IMSD) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. The long-term goal of the program is to enhance the diversity of biomedical research scientists in the Nations workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-intensive institutions (i.e., those with a 3-year average of NIH Research Project Grant funding equal to or above $7.5 million total costs).

Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)

November 19, 2020

Funding Opportunity RFA-ES-21-001 from the NIH Guide for Grants and Contracts. The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding the effects of environmental exposure on peoples health.

Diabetes Research Centers (P30 Clinical Trial Optional)

November 19, 2020

Funding Opportunity RFA-DK-20-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2020 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org ,

Notice of Intent to Publish a Funding Opportunity Announcement for Cellular Cancer Biology Imaging Research (CCBIR) Program (U54 Clinical Trial Not Allowed)

November 19, 2020

Notice NOT-CA-21-016 from the NIH Guide for Grants and Contracts

Contraceptive Development Research Centers Program (P50 Clinical Trial Optional)

November 19, 2020

Funding Opportunity RFA-HD-22-003 from the NIH Guide for Grants and Contracts. The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Development Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. Additionally, it allows for behavioral/social science, including market research to test user acceptability, research projects that are responding and well-coordinated to the contraceptive product being developed. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

November 19, 2020

Funding Opportunity PAR-21-058 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.